Stoke Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Stoke Therapeutics, Inc. filed a Form 8-K dated September 22, 2026, with the report signed on September 25, 2026. The filing concerns changes to the company’s board of directors and does not report operating or period-end financial results.
Board and governance changes
- Edward M. Kaye, M.D. resigned as a Class III director and as a member of the Research and Development Committee, effective September 23, 2026.
- The filing states that Dr. Kaye’s resignation was not due to any disagreement with the company.
- Effective September 23, 2026, the board appointed Alexander (Bo) Cumbo as a Class III independent director to fill the vacancy. His term expires at the 2028 annual meeting of stockholders.
- The filing states that Mr. Cumbo had no arrangement or understanding relating to his selection and no reportable related-party transaction under Item 404(a) of Regulation S-K.
- Mr. Cumbo entered into the company’s standard director and officer indemnification agreement.
Compensation and equity award
- Mr. Cumbo will receive an annual cash retainer of $45,000 for board service.
- He received an initial option to purchase 39,674 shares of common stock under the 2019 Equity Incentive Plan.
- The option had a target grant-date fair value of approximately $724,000 under ASC 718 and will vest in 12 substantially equal quarterly installments.
Financial metrics and outlook
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, operating outlook, or other financial performance metrics. It also does not disclose material changes versus a prior comparable period.
Risks, contingencies, and unusual items
The principal disclosed items are the director transition and the related cash and equity compensation. The filing does not identify disagreements, litigation, contingencies, or other unusual matters associated with the transition.
Investor verification points
- Verify the effective dates of Dr. Kaye’s resignation and Mr. Cumbo’s appointment.
- Review the company’s director compensation program and the terms of the 39,674-share option, including the exercise price and other award conditions, which are not provided in the filing text.
- Confirm Mr. Cumbo’s independence and committee assignments following the appointment.
- Assess the potential dilution and stock-based compensation impact of the option grant in subsequent SEC filings.